Centivax Secures $37 Million to Propel Universal Flu Vaccine and Further Pipeline Development Centivax, Inc. has successfully closed a $37 million financing round, advancing its universal flu vaccine, Centi-Flu 01, towards Phase 2 clinical trials while expanding its innovative therapeutic pipeline.

Centivax Secures $37 Million to Propel Universal Flu Vaccine and Further Pipeline Development #United_States #South_San_Francisco #Centivax #Universal_Immunity #Centi-Flu_01

Centivax Secures $45 Million Funding to Develop Universal Flu Vaccine and Expand Immunology Portfolio Centivax Inc. has successfully raised $45 million in an oversubscribed Series A funding round aimed at developing a universal flu vaccine and expanding their immunology portfolio.

Centivax Secures $45 Million Funding to Develop Universal Flu Vaccine and Expand Immunology Portfolio #United_States #South_San_Francisco #Vaccine_Development #Centivax #Universal_Immunity